Lleó, Alberto http://orcid.org/0000-0002-2568-5478
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Pegueroles, Jordi
Karikari, Thomas K. http://orcid.org/0000-0003-1422-4358
Carmona-Iragui, María
Ashton, Nicholas J.
Montal, Victor
Barroeta, Isabel
Lantero-Rodríguez, Juan http://orcid.org/0000-0002-7426-678X
Videla, Laura
Altuna, Miren http://orcid.org/0000-0001-9709-5314
Benejam, Bessy
Fernandez, Susana
Valldeneu, Silvia
Garzón, Diana
Bejanin, Alexandre http://orcid.org/0000-0002-9958-0951
Iulita, Maria Florencia
Camacho, Valle http://orcid.org/0000-0003-0748-0847
Medrano-Martorell, Santiago http://orcid.org/0000-0002-6586-7284
Belbin, Olivia http://orcid.org/0000-0002-6109-6371
Clarimon, Jordi
Lehmann, Sylvain
Alcolea, Daniel http://orcid.org/0000-0002-3819-3245
Blesa, Rafael
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Fortea, Juan
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Pi14/01126)
Fundació la Marató de TV3 (20141210)
"la Caixa" Foundation
Article History
Received: 26 October 2020
Accepted: 9 June 2021
First Online: 14 July 2021
Competing interests
: Dr. Lleó has served as a consultant or at advisory boards for Fujirebio-Europe, Roche, Biogen and Nutricia. In addition, Dr. Lleó has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. Dr. Zetterberg has served as a consultant or at advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Dr. Alcolea has served as a consultant or at advisory boards for Krka Farmacéutica S.L., Fujirebio-Europe, Roche Diagnostics and Nutricia. In addition, Dr. Alcolea has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. Dr. Blennow has served as a consultant or at advisory boards for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Dr. Fortea has served as a consultant or at advisory boards for AC Immune, Novartis, and Merck. In addition, Dr. Fortea has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. The other authors declare no competing interests.